Summary
Interferon has been shown to be effective in the treatment of chronic hepatitis C but the optimal treatment regime has not yet been defined. Studies using 3 million units (MU) of interferon thrice weekly (tiw) for 6 months have shown normalization of serum alanine aminotransferase (ALT) in about 50% of patients, but relapse occurs in at least 50% of responders after interferon is stopped. The aims of this study were to determine whether 5 MU of interferon tiw produces a higher response rate than 3 MU tiw and to examine if the higher dose results in more sustained remissions. In addition, factors that are associated with a more or less favourable response to interferon treatment were sought. Overall, 65% of patients responded and no advantage of the higher dose therapy was found, either in terms of response or relapse rate after treatment. The presence of cirrhosis on the pre-treatment liver biopsy was associated with a poor response rate to interferon and a trend towards a higher relapse rate. Risk factor for acquisition of disease was also related to likelihood of response but not relapse. We conclude that two thirds of Australian patients with chronic hepatitis C initially respond to interferon treatment. Positive predictors of response are intravenous drug use as a risk factor and histologically less severe liver disease. Relapse occurs in two thirds of all responders.
Similar content being viewed by others
References
Davis GL. Recombinant α-interferon treatment of non-A, non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol 1990;11(suppl 1): S72–77.
Farrell GC. Treatment of chronic hepatitis C with alpha interferon. J Gastroenterol Hepatol 1991;6(suppl 1): 36–40.
Di Bisceglie AM, Hoofnagle JH. Therapy of chronic hepatitis C with α-interferon: the answer? or more questions? Hepatology 1991;13: 601–603.
Lin R, Schoeman MN, Craig PI, et al. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C. Aust NZ J Med 1991;21: 387–392.
Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101: 497–502.
Brouwer JT, Kleter GEM, Nevens F, et al. Benelux multicenter trial of alpha interferon treatment for chronic hepatitis C: standard vs high dose therapy monitored by biochemical and virological markers (interim analysis). Gut 1992(suppl);(in press).
Marcellin P, Boyer N, Giostra E, et al. Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13: 393–397.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Lin, R., Liddle, C., Farrell, G.C. et al. Alpha-interferon 2b in the treatment of chronic hepatitis C: interim report of the first multicentre Australian trial. Gastroenterol Jpn 28 (Suppl 5), 101–103 (1993). https://doi.org/10.1007/BF02989217
Issue Date:
DOI: https://doi.org/10.1007/BF02989217